TCL Archive DeVita Resigns As No. 2 At Sloan-Kettering To “Pursue Clinical Research,” Hospital Says May 31, 1991
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
